Zhang Linlin, Shu Ruichen, Wang Chunyan, Wang Haiyun, Li Nan, Wang Guolin
Department of Anesthesiology, Tianjin Medical University General Hospital, Tianjin 300052, PR China; Tianjin Research Institute of Anesthesiology, Tianjin 300052, PR China.
Brain Res Bull. 2014 Jul;106:47-55. doi: 10.1016/j.brainresbull.2014.05.005. Epub 2014 Jun 18.
Although NMDAR trafficking mediated by GSK-3β involvement in transmission of pronociceptive messages in the spinal cord has been confirmed by our previous studies, whether NMDAR trafficking is implicated in peripheral sensitization remains equivocal. It is demonstrated that inflammation is associated with spinal NMDAR-containing nociceptive neurons activation and the maintenance of opioid induced pain hypersensitivity. However, whether and how hydrogen-rich saline, as an effective anti-inflammatory drug, could prevent hyperalgesia through affecting peripheral sensitization caused by NMDAR activation remains to be explored.
To test these effects, hydrogen-rich saline (2.5, 5 or 10 ml/kg) was administrated intraperitoneally after remifentanil infusion, NMDAR antagonist MK-801 or GSK-3β inhibitor TDZD-8 was administrated intravenously before remifentanil infusion in rats. We examined time course of hydrogen concentration in blood after hydrogen-rich saline administration. Mechanical and thermal hyperalgesia were evaluated by measuring PWT and PWL for 48 post-infusion hours, respectively. Western blotting and real-time qPCR assay were applied to analyze the NR1 membrane trafficking, GSK-3β expression and activity in DRG. Inflammatory mediators (TNF-α, IL-1β, and IL-6) expressions in DRG were also analyzed.
We found that NR1 membrane trafficking in DRG increased, possibly due to GSK-3β activation after remifentanil infusion. We also discovered that hydrogen-rich saline not 2.5 ml/kg but 5 and 10 ml/kg could dose-dependently attenuate mechanical and thermal hyperalgesia without affecting baseline nociceptive threshold, reduce expressions of inflammatory mediators (TNF-α, IL-1β, and IL-6) and decrease NR1 trafficking mediated by GSK-3β, and minimal effective concentration was observed to be higher than 10 μmol/L, namely peak concentration in arterial blood after administration of HRS 2.5 ml/kg without any influence on hyperalgesia.
Our results indicated that antihyperalgesic effect of hydrogen-rich saline might depend predominantly on its ability to reverse NR1 trafficking via inhibition of GSK-3β activity in DRG in a dose-dependent manner.
尽管我们之前的研究已证实由糖原合成酶激酶-3β(GSK-3β)介导的N-甲基-D-天冬氨酸受体(NMDAR)转运参与脊髓中伤害性感受信息的传递,但NMDAR转运是否与外周敏化有关仍不明确。已证实炎症与脊髓中含NMDAR的伤害性神经元激活及阿片类药物诱导的疼痛超敏反应的维持有关。然而,作为一种有效的抗炎药物,富氢盐水是否以及如何通过影响由NMDAR激活引起的外周敏化来预防痛觉过敏仍有待探索。
为测试这些作用,在大鼠瑞芬太尼输注后腹腔注射富氢盐水(2.5、5或10 ml/kg),在瑞芬太尼输注前静脉注射NMDAR拮抗剂MK-801或GSK-3β抑制剂TDZD-8。我们检测了富氢盐水给药后血液中氢浓度的时间进程。分别通过测量输注后48小时的机械性痛阈(PWT)和热痛阈(PWL)来评估机械性和热痛觉过敏。应用蛋白质免疫印迹法和实时定量聚合酶链反应检测分析背根神经节(DRG)中NR1的膜转运、GSK-3β的表达及活性。还分析了DRG中炎症介质(肿瘤坏死因子-α、白细胞介素-1β和白细胞介素-6)的表达。
我们发现瑞芬太尼输注后DRG中NR1的膜转运增加,这可能是由于GSK-3β激活所致。我们还发现,富氢盐水不是2.5 ml/kg,而是5和10 ml/kg能够剂量依赖性地减轻机械性和热痛觉过敏,而不影响基线痛觉阈值,降低炎症介质(肿瘤坏死因子-α、白细胞介素-1β和白细胞介素-6)的表达,并减少由GSK-3β介导的NR1转运,且观察到最小有效浓度高于10 μmol/L,即注射2.5 ml/kg富氢盐水后动脉血中的峰值浓度,对痛觉过敏无任何影响。
我们的结果表明,富氢盐水的抗痛觉过敏作用可能主要取决于其通过抑制DRG中GSK-3β的活性以剂量依赖性方式逆转NR1转运的能力。